Astudiaethau Achos: canser

Prosiectau cyfredol KESS 2 mewn partneriaeth â Gofal Canser Tenovus

Tenovus Cancer Care

Mae’r ymchwil sy’n cael ei chefnogi drwy KESS 2 a Gofal Canser Tenovus wedi gwneud cymaint eisoes i helpu cleifion â chanser. Dyma brosiectau sy’n cael eu cefnogi ar hyn o bryd gan Ofal Canser Tenovus gyda KESS 2, i barhau i helpu pobl y mae canser yn effeithio arnynt.   2018 Amlinellu sut mae… Darllen mwy »

Diffinio sut mae defnyddio systemau model cohort newydd cyn-glinigol

(English) The Student Perspective by Huw Morgan, Cardiff University. The project that I am working on is in partnership with Tenovus. I am looking at the utility of a novel pre-clinical cohort model system, which is in relation to breast cancer. The discovery and development of new drugs at any given time point is termed the drug pipeline and it can be broken down into four broad categories: i) discovery, ii) pre-clinical trials, iii) clinical trials and iv) marketing.

Darllen mwy »

Deall rôl gwrth/pro tiwmorigenig INF-Y mewn canser y coluddyn

Safbwynt Myfyriwr gan Chris Towers, Prifysgol Caerdydd. Mae fy mhrosiect KESS yn ystyried rôl molecwl o’r enw gama interfferon yn y system imiwnedd, ac rwy’n ceisio gweld p’un ai a yw’n cael effaith gadarnhaol ynteu effaith negyddol ar ganser colorectal. Mae fy mhrosiect yn bwysig gan mai canser colorectal yw’r ail ganser mwyaf difrifol o ran marwolaethau ac o ganlyniad mae’n hynod o bwysig dod o hyd i ffordd o leddfu’r dioddefaint a achosir gan yr afiechyd hwn.

Darllen mwy »

Datblygu system newydd o roi pro-gyffur quinon ar gyfer canser (Cyflwyniad)

(English) The chemotherapy agents which are in current use are highly toxic compounds and are also non selective meaning that in effect the patient is being medically “poisoned” in the hope that the cancer will die first. Prodrug technology allows for the selective deployment of highly toxic drugs into cancer cells, whilst healthy cells are left relatively unaffected.

Darllen mwy »